In this recent interview with Joel Dunning, Robert Cerfolio discusses his philosophies regarding thoracic surgery and life.
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Thoracic
September 1, 2015
In this video, the authors demonstrate a left 3-arm robotic approach for extended thymectomy.
August 26, 2015
Investigators from Stanford developed a nine-gene expression predictor for survival outcome in early-stage nonsquamous NSCLC. They developed and validated a quantitative real-time polymerase chain reaction assay easily applicable to routinely obtained paraffin-embedded tumor specimens.
August 24, 2015
This video illustrates a laparoscopic, robot-assisted hemidiaphragm plication.
August 22, 2015
Among patients with blunt trauma, the authors studied the implications of pneumomediastinum identified on CT. The incidence was 2.2%. Pneumomediastinum was associated with a 4-fold increase in mortality, a 2-fold increase in length of stay, and a 3-fold increase in ICU stay. Air in the posterior mediastinum, air in all mediastinal compartments, an
August 22, 2015
This comprehensive review outlines changes in the WHO classification of lung tumors, chagnes that will affect our clinical practice in the near future.
August 20, 2015
Thus far, only 3 randomized controlled trials (RCTs) have compared stereotactive ablative radiotherapy (SABR) versus surgery in patients with early stage NSCLC (STARS trial, ROSEL trial, and ACOSOG Z4099 trial). Unfortunately all 3 were unable to meet the accrual goals and were closed early.
August 20, 2015
This expert opinion editorial is published in JTCVS in response to the article by Chang and colleagues. Meyers and colleagues begin by emphasizing that a large randomized controlled trial (RCT) would be the best way to answer the question of whether SABR or lobectomy is superior treatment for patients with early stage NSCLC.
August 20, 2015
This is a letter in response to the article by Chang and colleagues.
August 20, 2015
This is a letter in response to the article by Chang and colleagues. The authors warn to interpret the findings of the original article, that SABR is better tolerated and might lead to improved survival compared to surgery for good risk patients with clinical stage I NSCLC, with caution. They highlight two pitfalls of the original study.